BGI Genomics and Fudan University Develop 1,341 Gene Signature to Overcome Biopsy Bias in Liver Cancer Treatment

BGI Genomics reveals a new molecular roadmap for intrahepatic cholangiocarcinoma, using a stable gene signature to improve biopsy accuracy and targeted therapy.

By: AXL Media

Published: Apr 1, 2026, 10:08 AM EDT

Source: Information for this report was sourced from BGI Genomics

Navigating the Molecular Chaos of Intratumoral Heterogeneity

Intrahepatic cholangiocarcinoma stands as the second most prevalent primary liver cancer, yet it remains notoriously difficult to treat due to its concealed nature and high level of internal diversity. A significant barrier in current clinical practice is that a single biopsy often fails to capture the full biological landscape of a tumor, as different regions can exhibit vastly different molecular traits. Research from BGI Genomics and Zhongshan Hospital shows that traditional classification methods misidentify more than 25 percent of tumors due to this sampling bias. To solve this, the team identified a specific set of genes characterized by low internal variation but high differences between patients. This framework, known as the LIHV gene set, allows clinicians to filter out biological noise and achieve a more stable diagnosis regardless of where the biopsy is taken.

Categorizing Aggressive and Metabolic Subtypes for Better Outcomes

The newly developed 1,341 gene signature categorizes iCCA into five molecular subtypes, each possessing a unique clinical profile and prognosis. The Inflammatory subtype, or SI, is identified as the most aggressive form, often linked to KRAS mutations and high levels of clinical markers like CA19-9. Conversely, the Metabolic subtype, known as SII, presents a biological paradox characterized by a high mutation burden and an immunosuppressive environment. While these tumors are often resistant to standard care, the researchers suggest they may be particularly sensitive to combination immunotherapies. By isolating these specific genetic signatures, the medical community can move away from generalized treatments and toward a system that recognizes the specific metabolic and inflammatory drivers of an individual's disease.

The Complexity of Small Bile Duct Type Classifications

A significant portion of the study focuses on the SIII group, which encompasses atypical, immune silent, and neurodegenerative subtypes primarily found in small bile duct infections. These variations generally offer a more favorable clinical outlook compared to the inflammatory subtype but require specialized genetic mapping to manage effectively. For instance, the SIII-2 subgroup is frequently enriched with BAP1 mutations, while SIII-3 shows a prevalence of IDH1 and IDH2 mutations. Understand...